122 related articles for article (PubMed ID: 27925025)
1. Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian Unified National Health System.
Scopel CT; Chaves GC
Cad Saude Publica; 2016 Dec; 32(11):e00113815. PubMed ID: 27925025
[TBL] [Abstract][Full Text] [Related]
2. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand.
Ford N; Wilson D; Costa Chaves G; Lotrowska M; Kijtiwatchakul K
AIDS; 2007 Jul; 21 Suppl 4():S21-9. PubMed ID: 17620749
[TBL] [Abstract][Full Text] [Related]
3. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
Simpson KN; Baran RW; Kirbach SE; Dietz B
Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
[TBL] [Abstract][Full Text] [Related]
4. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
6. Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?
Ahmed BS; Phelps BR; Reuben EB; Ferris RE
Trans R Soc Trop Med Hyg; 2014 Jan; 108(1):49-54. PubMed ID: 24300443
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004-2011.
Luo J; Oliveira MA; Ramos MB; Maia A; Osorio-de-Castro CG
BMC Public Health; 2014 Apr; 14():367. PubMed ID: 24735589
[TBL] [Abstract][Full Text] [Related]
8. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
Rosenberg ST
Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
[TBL] [Abstract][Full Text] [Related]
9. Civil society strategy for the compulsory licensing of lopinavir/ritonavir: the Brazilian case.
Vieira MF; Reis R; Chaves G
HIV AIDS Policy Law Rev; 2008 Dec; 13(2-3):80-1. PubMed ID: 19297771
[TBL] [Abstract][Full Text] [Related]
10. Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?
Meiners C; Sagaon-Teyssier L; Hasenclever L; Moatti JP
PLoS One; 2011; 6(8):e23478. PubMed ID: 21858138
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral purchasing and prescription practices in Mexico: constraints, challenges and opportunities.
Chaumont C; Bautista-Arredondo S; Calva JJ; Bahena-González RI; Sánchez-Juárez GH; González de Araujo-Muriel A; Magis-Rodríguez C; Hernández-Ávila M
Salud Publica Mex; 2015; 57 Suppl 2():s171-82. PubMed ID: 26545133
[TBL] [Abstract][Full Text] [Related]
12. Drug firms lose patent rights lawsuit against South Africa's government.
Baleta A
Lancet; 2001 Apr; 357(9265):1347. PubMed ID: 11343755
[No Abstract] [Full Text] [Related]
13. Reforming antiretroviral price negotiations and public procurement: the Mexican experience.
Adesina A; Wirtz VJ; Dratler S
Health Policy Plan; 2013 Jan; 28(1):1-10. PubMed ID: 22375026
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
Simpson KN; Rajagopalan R; Dietz B
Adv Ther; 2009 Feb; 26(2):185-93. PubMed ID: 19219410
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments.
Guennif S
Dev World Bioeth; 2017 Aug; 17(2):90-99. PubMed ID: 27699996
[TBL] [Abstract][Full Text] [Related]
16. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
[TBL] [Abstract][Full Text] [Related]
17. Brazilian policy of universal access to AIDS treatment: sustainability challenges and perspectives.
Greco DB; Simão M
AIDS; 2007 Jul; 21 Suppl 4():S37-45. PubMed ID: 17620751
[TBL] [Abstract][Full Text] [Related]
18. [Compulsory licensing of efavirenz in Brazil in 2007: contextualization].
Rodrigues WC; Soler O
Rev Panam Salud Publica; 2009 Dec; 26(6):553-9. PubMed ID: 20107711
[TBL] [Abstract][Full Text] [Related]
19. Strategies for price reduction of HIV medicines under a monopoly situation in Brazil.
Chaves GC; Hasenclever L; Osorio-de-Castro CG; Oliveira MA
Rev Saude Publica; 2015; 49():. PubMed ID: 26759969
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Broder MS; Chang EY; Bentley TG; Juday T; Uy J
J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
